Supraspinatus Tear Clinical Trial
Official title:
The Efficacy of Using Allogeneic Adipose-derived Mesenchymal Stem Cells and Human Amniotic Membrane (AAdMSC-HAM) Composite for Supraspinatus Tendon Repair Augmentation
This is a non-randomized clinical trial conducted in a single tertiary hospital which investigates the efficacy of allogeneic adipose-derived mesenchymal stem cells and human amniotic membrane (AAdMSC-HAM) composite for supraspinatus tendon repair augmentation
Status | Recruiting |
Enrollment | 24 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 35 Years to 75 Years |
Eligibility | Inclusion Criteria: - Suffering from complete/total tear of supraspinatus tendon for a duration of fewer than 12 months - Diagnosis is established based on clinical condition and ultrasonography or MRI examination Exclusion Criteria: - Patients with comorbid diseases: Diabetes Mellitus, Rheumatoid Arthritis, and other inflammatory diseases. - Patients presenting with other related injuries, such as fractures or dislocation around the shoulder joint. |
Country | Name | City | State |
---|---|---|---|
Indonesia | Dr. Soetomo General Academic Hospital/ Department Orthopaedic & Traumatology Faculty of Medicine Universitas Airlangga | Surabaya | East Java |
Lead Sponsor | Collaborator |
---|---|
Dr. Soetomo General Hospital |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Active range of motion (AROM) pre-surgery | Shoulder: flexion, extension, abduction, adduction, external rotation, internal rotation.
The tests are performed by two blinded assessor, and expressed in degrees. |
Pre-surgery | |
Primary | Active range of motion (AROM) at 12 months follow-up | Shoulder: flexion, extension, abduction, adduction, external rotation, internal rotation.
The tests are performed by two blinded assessor, and expressed in degrees. |
12 months | |
Secondary | Pain pre-surgery | Measured by visual analogue scales (VAS). Patients are asked to described their level of pain from the scale 0 to 10 (0 indicating no pain, 1-3 indicating mild pain, 4-6 indicating moderate pain, 7-9 indicating severe pain, and 10 indicating the worst, unbearable pain). The lower scores mean a better pain outcome | Pre-surgery Outcome | |
Secondary | Pain at follow-up 12 months | Measured by visual analogue scales (VAS). Patients are asked to described their level of pain from the scale 0 to 10 (0 indicating no pain, 1-3 indicating mild pain, 4-6 indicating moderate pain, 7-9 indicating severe pain, and 10 indicating the worst, unbearable pain). The lower scores mean a better pain outcome | 12 months | |
Secondary | Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery | DASH score is a self-assessment of symptoms and function of the entire upper extremity comprising 30 items. Each item consists of five levels of answers (1=no difficulty/symptoms, 2=mild difficulty/symptoms, 3=moderate difficulty/symptoms, 4=severe difficulty/symptoms, and 5=extreme difficulty (unable to do)/symptoms). The scores are then used to calculate a scale score ranging from 0 (no disability) to 100 (most severe disability). Greater DASH scores reflect greater disability (worse outcome). | Pre-surgery | |
Secondary | Disabilities of the Arm, Shoulder, and Hand (DASH) score at follow-up 12 months | DASH score is a self-assessment of symptoms and function of the entire upper extremity comprising 30 items. Each item consists of five levels of answers (1=no difficulty/symptoms, 2=mild difficulty/symptoms, 3=moderate difficulty/symptoms, 4=severe difficulty/symptoms, and 5=extreme difficulty (unable to do)/symptoms). The scores are then used to calculate a scale score ranging from 0 (no disability) to 100 (most severe disability). Greater DASH scores reflect greater disability (worse outcome). | 12 months | |
Secondary | Constant-Murley Score (CS) pre-surgery | The scoring system records individual parameters and provides an overall clinical functional assessment. It consists of 4 domains: pain, activities of daily living (ADL), mobility, and power/strength. Pain and ADL are self-assessed, while all other items are assessed by the blinded examiner. A higher score shows a better function (100 as the best), while a lower score shows a worse function (0 as the worst). | Pre-surgery | |
Secondary | Constant-Murley Score (CS) at follow-up 12 months | The scoring system records individual parameters and provides an overall clinical functional assessment. It consists of 4 domains: pain, activities of daily living (ADL), mobility, and power/strength. Pain and ADL are self-assessed, while all other items are assessed by the blinded examiner. A higher score shows a better function (100 as the best), while a lower score shows a worse function (0 as the worst). | 12 months | |
Secondary | Tear recurrence (re-tear) | A systematic review (D'Ambrosi et al., 2019) showed that re-tear rates after rotator cuff repair with scaffolds were 17.97%. We hypothesize that the augmentation using HAM (as scaffold) seeded with AAdMSC would further lower the re-tear rates. We plan to record the recurrence of supraspinatus tendon tear (if any) based on radiographic evaluation with ultrasonography, which will then be confirmed with MRI. Ultrasonography provides an excellent anatomical evaluation of soft tissue which is able to assess any alterations during active locomotion. However, due to its user-dependent nature, we will also confirm the findings with MRI examination. Any grade of re-tear (grade I-III as evaluated by ultrasonography and confirmed with MRI) will be counted in and classified as "re-tear". When the patients do not complain about any symptoms of re-tear, we will record them as "no re-tear". | Throughout the study duration (12 months), recorded as the first time complained by the patients (i.e. after "n" months). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05590494 -
Novel Treatment for Rotator Cuff Tears
|
N/A | |
Enrolling by invitation |
NCT01414764 -
Does Autologous Conditioned Plasma Enhance Rotator Cuff Tendon Healing After Surgery?
|
Phase 3 | |
Active, not recruiting |
NCT04444076 -
Clinical Trial on the Effect of REGENETEN Bioinductive Implant in the Supraspinatus Tendon Repair.
|
N/A | |
Recruiting |
NCT05660031 -
Treatment of the Biceps With Concomitant Supraspinatus Tears
|
N/A | |
Completed |
NCT03942679 -
Platelet Rich Plasma and Supraspinatus Tear
|
N/A | |
Completed |
NCT03084068 -
Use of Human Dehydrated Umbilical Cord Allograft in Supraspinatus Tendon Repair
|
N/A | |
Enrolling by invitation |
NCT05335785 -
Efficacy of High Intensity Lazer Therapy in Partial Supraspinatus Tear
|
N/A |